Abstract
In their Policy Forum “Moving toward transparency of clinical trials” (7 March, p. [1340][1]), D. A. Zarin and T. Tse caution that “FDAAA 801 still leaves areas of 'opacity.'” We would like to point out another loophole: FDAAA 801 will only cover future drugs. The thousands of drugs on the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
